Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies
This study is currently recruiting participants.
Study NCT00038051   Information provided by M.D. Anderson Cancer Center
First Received: May 24, 2002   Last Updated: May 8, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myeloproliferative Disorders
Additional conditions recognized in this trial
Anemia
Anemia, Refractory
Anemia, Refractory, with Excess of Blasts
Disease
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Myelodysplastic Syndromes
Myelodysplastic-Myeloproliferative Diseases
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Interventions listed in this trial
Hum-195/rGel
Additional drug interventions recognized in this trial
Immunotoxins
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
M.D. Anderson Cancer Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services